Publication: Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis
Issued Date
2005-12-01
Resource Type
ISSN
13596535
Other identifier(s)
2-s2.0-30444444706
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Antiviral Therapy. Vol.10, No.8 (2005), 937-943
Suggested Citation
Reshma S. Autar, Ferdinand W.N.M. Wit, Jongkol Sankote, Apicha Mahanontharit, Thanomsak Anekthananon, Piroon Mootsikapun, Khanjtta Sujaikaew, David A. Cooper, Joep M.A. Lange, Praphan Phanuphak, Kiat Ruxrungtham, David M. Burger Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antiviral Therapy. Vol.10, No.8 (2005), 937-943. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16730
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis
Other Contributor(s)
Abstract
Objectives: In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively. However, limited data are available about whether or not nevirapine and rifampin can be safely co-administered without the plasma concentration of nevirapine falling below therapeutic levels. Methods: Blood samples for determination of nevirapine plasma concentrations were collected from patients using nevirapine 200 mg twice daily with or without concomitant rifampin. Bivariate and multivariate linear regression models were used to investigate factors possibly related to nevirapine concentrations. Results: We received 74 blood samples from patients using nevirapine plus rifampin, and collected blood samples from an equal number of controls using nevirapine only. Groups were similar for age, gender, weight, height and body mass index (BMI). In the rifampin group the mean nevirapine concentration was 5.47 ± 2.66mg/l, whereas in the control group the mean nevirapine concentration was 8.72 ± 3.98 mg/l. In the rifampin group seven nevirapine trough concentrations were low (<3.1 mg/l), while in the control group two patients had low nevirapine trough concentrations (P=0.164). In the multivariate linear regression analysis, corrected for time after drug intake, the use of rifampin was significantly (P<0.001) associated with lower nevirapine plasma concentrations, whereas higher BMI reached borderline significance (P=0.065). Conclusion: Although nevirapine plasma concentrations were 3.3 mg/l lower when co-administered with rifampin, still more than 86% of these patients had nevirapine plasma concentrations >3.1 mg/l. Our results suggest that from a pharmacological point of view the majority of Thai coinfected patients, who have low BMIs, reach nevirapine plasma concentrations that are adequate for treatment of HIV. However this can only be undertaken if nevirapine plasma concentration monitoring is available and can be closely followed. © 2005 International Medical Press.